Kathleen M. Boozang

Dean Kathleen M. Boozang (2019)

Professor of Law

  • Degrees:

  • LL.M., Yale Law School | J.D., Washington University School of Law | B.S., Boston College
  • Contact:

  • [email protected]
  • Tel: 973-642-8547
  • Curriculum Vitae
  • Courses:

  • Pharmaceutical and Medical Device, Marketing & Compliance, Health Law, Death and Dying

Kathleen Boozang was Dean of Seton Hall Law from July 2015 through December 2022. She has also served as Vice Provost for Academic Affairs and twice as Associate Dean.  For most of her academic career, in addition to teaching and scholarship, Professor Boozang has been extremely entrepreneurial in connection with a variety of disciplines and teaching modalities.  Professor Boozang has also been engaged throughout her career, both within and outside of academia, in any number of boards, editorial positions, and professional service organizations.

Professor Boozang came to Seton Hall in 1990 as the founder of the Law School’s top-ranked Center for Health & Pharmaceutical Law. As Associate Dean, she also established Seton Hall Law's graduate degrees, Division of Online Learning and global life sciences compliance training programs. As Dean, she worked with colleagues to create ethics and compliance training in privacy and gaming. Boozang also created Seton Hall Law’s extremely successful graduate degree program for non-lawyers in compliance, privacy, risk management and creative industries.

Professor Boozang’s first two initiatives upon becoming dean were to create the position of Assistant Dean of Equity, Diversity and Engagement and to convert the Law School’s part-time evening program to an innovative Weekend hybrid program. Seton Hall Law aspires to equality of outcomes for every student and employee, and this philosophy informed Professor Boozang’s leadership. The Weekend program is an example of expanding access to the legal profession for mid-career professionals; the inaugural class of 2021 achieved a first-time bar pass rate of 87%.

Professor Boozang has taught a variety of health law courses in person and online including health law, health care fraud and corruption, tax-exempt organizations, and death and dying. Professor Boozang’s scholarship has evolved throughout her career.  Her research includes articles on bioethical issues, nonprofit governance with a special focus on religiously-sponsored hospitals, the legal implications of providing and paying for complementary and alternative medicine, and the law related to fraud, compliance and conflicts of interest. Professor Boozang has taught Torts, Contracts and Professional Responsibility in the One L curriculum.

Professor Boozang is a Fellow of The Hastings Center, an independent nonprofit bioethics research institute, as well as a Fellow of the American Bar Foundation, an honorary organization of legal practitioners. She is also a member of the American Law Institute and participated on the consultant groups for the Principles of Nonprofit Law and Corporate Compliance. She has served on the Editorial Board of the Journal of Health and Life Sciences Law and is a past editor-in-chief of the Journal of Law, Medicine & Ethics. She is past president of the American Society of Law, Medicine & Ethics (ASLME) and also previously sat on the Advisory Board of the Journal of Health Law. Professor Boozang served for many years on the Board of Directors of the American Health Lawyers Association (AHLA) and remains involved in many AHLA projects.

Professor Boozang is a frequent member of ABA law school site accreditation teams.

Professor Boozang has served on multiple boards, including the Board of Trustees of the St. Joseph Healthcare System in New Jersey, ASLME, AHLA, and the Cathedral Health System. In 2013, the ASLME conferred upon Professor Boozang the Jay Healy Health Law Teacher Award.

Professor Boozang graduated from Washington University School of Law in St. Louis, Missouri, where she was inducted into the Order of the Coif and served as the managing editor of Law Quarterly (now the Law Review). She received her LL.M. from Yale Law School in 1990.

Professor Boozang is on sabbatical in Spring 2023 as a visiting scholar at the Petrie- Flom Center at Harvard Law School.



Light Unseen?, 58 J. CATH. LEGAL STUDIES 5 (2020) (invited essay)

Responsible Corporate Officer Doctrine: When is Falling Down on the Job a Crime?, 6 J. Health L & Pol'y 77 (2012)

"Monitoring" Corporate Corruption: DOJ's Use of Deferred Prosecution Agreements in Health Care, 35 Am. J.L. Med. 89 (Spring 2009) (with Simone Handler-Hutchinson)

A Civil Law Analysis: The Place of Religion in Treatment Termination Decision-Making, 15 Temp. Civ. Rts. L. Rev. 345 (2007)

Does Director Independence Improve Nonprofit Governance?, 75 Tenn. L. Rev. 83 (2007)

Mission, Margin and Trust in the Nonprofit Healthcare Enterprise, 5 Yale J. Health Pol’y, L. and Ethics 1 (2005) (T.L. Greaney)

Therapeutic Placebos: Making the Case for Patient Deception, 54 Fla. L. Rev. 687 (2002)

CAM for Kids, 1 Houston J. Health L. & Pol'y 109 (2001)

Is the Alternative Medicine? Managed Care Apparently Thinks So, 32 Conn. L. Rev. 567 (2000)

An Intimate Passing: Restoring the Role of Family and Religion in Dying, 58 U. Pitt. L. Rev. 549 (1997)

The Survival of Religious Hospitals in a World of Reformed Health Care, 31 Houston L. Rev. 1429 (1995)

Death Wish: Resuscitating Self-Determination for the Critically Ill, 35 Ariz. L. Rev. 23-85 (1993)


Entry: Organizational Ethics in the Healthcare Sector, in Bioethics, Bruce Jennings ed., 4th Edition (2014)

Legal and Ethical Issues in Complemantary and Alternative Medicine, in Complementary and Alternative Medicine: An Evidence Based Approach, Spencer & Jacobs (John Spencer & Joe Jacobs) (2003)

Problems and Conflicts Between Law and Morality in a Free Society, in Is There a Right to Life at the End of Life?, (James E. Wood & Derek Davis) (1994)


The New Relator: In-House Counsel and Compliance Officers, 6 J. Health & Life Sciences L. 16 (2012)

Toward Evidence-Based Conflicts of Interest Training for Physician-Investigators, J L Med Ethics (2012) (with Carl Coleman and Kate Greenwood)

Transparency: It May Not Be Sufficient, 4 Life Science Compliance 14 (2012)

An Argument Against Embedding Conflicts of Interest Disclosures in Informed Consent, 4 J.H. & Life Sciences L. 230 (2011) (with Carl H. Coleman and Kate Greenwood)

A New Pathway to Market for Biosimilars, 4 J. H & Life Sciences L. 121 (2010) (with Judith Toffentti)

Board Independence and Transparency: Searching for the Key to Good Governance, 1 J. Health & Life Sci. L. 127 (2009)

Independence and Transparency: Keys to Good Corporate Governance, 1 J. Health & Life Sciences L. 127 (2008)

Independence and Transparency: Keys to Good Corporate Governance, 1 J. Health & Life Sciences L. 127 (2008)

National Policy on CAM: The White House Commission Report, 31 J.L. Med. & Ethics 251 (2003)

Reconciling Health Care Needs and Religious Practices, 5 Gov't L. & Pol'y J. 23 (2003)

Western Medicine Opens the Door to Alternative Medicine, XXIV J. Law & Med. 185 (1998)

Developing a Public Policy Toward the Sectarian Provider: Accommodating Religious Beliefs and Obtaining Patient Access to Care, 24 J. Law, Medicine & Ethics 89 (1996)


The Role and Place of Compliance within Life Sciences: The Imperative of Chief Ethics and Compliance Officer Independence, (2018) (with Timothy Glynn)

The Ban on Off-Label Promotion and the False Claims Act: Analyzing a Decentralized, Public-Private Enforcement Regime, (2015) (collaborator)

Symposium: Is a For-Profit Structure a Viable Alternative for a Health Care Ministry?, Center for Religiously Affiliated Nonprofit Corporations & Center for Health & Pharmaceutical Law (2013) (In collaboration with University of St. Thomas)

The Limits of Disclosure as a Response to Financial Conflicts of Interest in Clinical Research, A White Paper by The Center for Health & Pharmaceutical Law & Policy (2010) (collaborator)

Conflicts of Interest in Clinical Trial Recruitment & Enrollment: A Call for Increased Oversight, A White Paper by The Center for Health & Pharmaceutical Law & Policy (2009) (collaborator)

Drug and Device Promotion: Charting A Course for Policy Reform, A White Paper by The Center for Health & Pharmaceutical Law & Policy (2009) (collaborator)


Case Study: The Abuse of Alternative Medicine?, 33 Hastings Center Rptr. 13-14 (2003)


AHLA Pharmaceutical and Medical Device Compliance Manual, First Ed. (2012) (with Simone Handler-Hutchinson)


The Aspirations and Challenges of Decision Aids, Arizona Syllabus (Spring 2013)


In Defense of the Responsible Corporate Officer Doctrine


Full list of presentations available in Curriculum Vitae

Aligning the Why and How of Corporate Compliance, Middle-East Healthcare Certificate Program (Dubai: January 2023, Paris: September 2022, APAC: 2022 Zoom) (Speaker)

Aligning the Why and How of Corporate Compliance, Middle-East Healthcare Certificate Program (Dubai: January 2023, Paris: September 2022, APAC: 2022 Zoom) (Speaker)

COVID Ethics Series, Crisis Standards of Care, Hackensack Meridian Medical School/Seton Hall University (Zoom February 2022) (Speaker)

Foreign Corrupt Practices Act, Seton Hall Law School, Asia-Pacific Healthcare Compliance Certificate Program (Zoom February 2022) (Facilitator)

International Pharmaceutical Compliance, Mini Summit 1: Basic Training: Basic Elements of the Compliance Field and Profession (May 2022) (Speaker)

New Jersey State Annual Bar Meeting, Women in Charge (May 2022) (Panelist)

New Jersey State Bar Association, Health Law Section, The Life Cycle of a Medical Staff Peer Review Fair Hearing Process (March 2022) (Facilitator)

ETHICS, The Future of Compliance (Paris, November 2021) (Speaker)

COVID Ethics Series: Resource Allocation, Did Provider Boards Fall Down on the Job?, Hackensack Meridian Medical School/Seton Hall University (November 2020) (Speaker)

J Cath Legal Studies 2020 Symposium, A Light Unseen: A History of Catholic Legal Education in the United States, St. John’s University School of Law (February 2020) (Speaker)

Patterson Belknap RBG Podcast, Ledbetter v. Goodyear (December 2020) (Panelist)

2019 Global Compliance Congress, How Third Party Relationships Can Define Your Company’s Reputation (London: November 2019) (Moderator)

20th Annual Pharmaceutical and Medical Device Congress, Lessons Learned from Enforcement Actions,  Washington D.C. (November 2019) (Panelist)

Donald S. Kent Memorial Lecture, A Comparison of the Differences between Legal and Medical Education, New Jersey Medical Society (Fall 2017) (Co-Speaker)

Healthcare Fraud: A Crippling Problem, A Cash Cow, or a Rogue (DOJ) Agenda?, Yale Alumni Assn (Fall 2017)

Getting Students to Talk, ASLME Health Law Teachers Conference, Saint Louis University School of Law (Spring 2015) (Panelist)

The Future of the Compliance Profession, AdvaMed and Eucomed Annual Meeting, Athens, Greece (Spring 2015) (Panelist)

Off-Label Treatment: Use of Cancer Drugs Outside of Conventional Trials and Government Approvals, The Judges and Lawyers Breast Cancer Alert and Women’s Bar Ass’n of the State of New York, New York City Bar Ass’n (Fall 2014) (Speaker)

Annual Flora Barlotta Lecture: End of Life Care, Saint Barnabas Medical Center (Spring 2011)

U.S. Waste Fraud and Abuse Laws, E.U. Corporate Compliance Program (June 2011) (Paris, France)